Phuong-Thao Tran | Medicinal Chemistry | Best Researcher Award

Best Researcher Award

Phuong-Thao Tran
Hanoi University of Pharmacy, Vietnam

Phuong-Thao Tran
Affiliation Hanoi University of Pharmacy
Country Vietnam
Scopus ID 55908125500
Documents 51
Citations 660
h-index 17
Subject Area Medicinal Chemistry, neurodegenerative disorders, Alzheimer’s disease
Event International Academic Achievements & Awards
ORCID 0000-0003-4855-2544

Phuong-Thao Tran is a researcher at Hanoi University of Pharmacy, Vietnam, whose work centers on medicinal chemistry and the discovery of compounds relevant to neurodegenerative disorders, particularly Alzheimer’s disease.[1] This article presents her profile in the context of the Best Researcher Award at the International Academic Achievements & Awards event.

Abstract

Phuong-Thao Tran is a medicinal chemistry researcher affiliated with Hanoi University of Pharmacy. Her publications address the design and evaluation of enzyme inhibitors for Alzheimer’s disease, including inhibitors of human glutaminyl cyclase and acetylcholinesterase, together with related studies in cancer biology.[2] With 51 indexed documents and 660 citations, her record reflects sustained and recognized scholarly activity in drug discovery.

Keywords

Medicinal chemistry, Alzheimer’s disease, neurodegenerative disorders, glutaminyl cyclase inhibitors, acetylcholinesterase, structure–activity relationship, computational drug design.

Introduction

Neurodegenerative disorders, especially Alzheimer’s disease, remain among the most difficult challenges in modern therapeutics. Medicinal chemists contribute by identifying molecular targets and designing compounds that can modulate them. Phuong-Thao Tran works in this field at Hanoi University of Pharmacy, combining synthetic chemistry, structure–activity analysis and computational approaches.[1] Her work has appeared in journals such as the Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry, ACS Omega and Cancers.

Research Profile

According to Scopus, the researcher’s author record (ID 55908125500) includes 51 documents, 660 citations and an h-index of 17.[1] Her principal subject areas are medicinal chemistry and neurodegenerative disorders, with a particular emphasis on Alzheimer’s disease. Her ORCID record provides a further public listing of her scholarly outputs.[5]

Research Contributions

Her contributions can be grouped into several themes:

  • Glutaminyl cyclase inhibitors. Rational design of potent human glutaminyl cyclase inhibitors as candidate anti-Alzheimer’s agents, together with structure–activity studies of inhibitors built on an imidazolyl propyl thiourea template.[2][3]
  • Acetylcholinesterase studies. Computational and experimental work on predicting ligand affinity and identifying possible inhibitors through umbrella sampling and machine learning.[4]
  • Cancer biology. A review of the emerging role of circulating tumor cells in gastric cancer, indicating a broader biomedical scope.

Publications

Selected highly cited publications, with citation counts as listed in the supplied profile data, include:

  • “Discovery of potent human glutaminyl cyclase inhibitors as anti-Alzheimer’s agents based on rational design,” Journal of Medicinal Chemistry 60(6), 2573–2590 (2017); 64 citations.[2]
  • “Emerging role of circulating tumor cells in gastric cancer,” Cancers 12(3), 695 (2020); 60 citations.
  • “Structure Activity Relationship of Human Glutaminyl Cyclase Inhibitors Having an N-(5-Methyl-1H-imidazol-1-yl)propyl Thiourea Template,” Bioorganic & Medicinal Chemistry (2013); 45 citations.[3]
  • “Prediction of AChE-ligand affinity using the umbrella sampling simulation,” Journal of Molecular Graphics and Modelling 93, 107441 (2019); 43 citations.
  • “Identifying possible AChE inhibitors from drug-like molecules via machine learning and experimental studies,” ACS Omega 7(24), 20673 (2022); 35 citations.[4]

Research Impact

The researcher’s impact is reflected in citation metrics and in the longevity of her work. Publications from 2013 to 2022 continue to attract citations, and the most cited paper, on glutaminyl cyclase inhibitors, has 64 citations.[1] An h-index of 17 indicates that at least 17 of her documents have each been cited at least 17 times. Her combination of experimental and computational methods also supports the reuse of her findings in later drug-design studies.

Award Suitability

The Best Researcher Award at the International Academic Achievements & Awards event recognizes researchers with significant scholarly contributions.[5] Phuong-Thao Tran’s profile aligns with such criteria through:

  • A focused research agenda in medicinal chemistry and Alzheimer’s disease therapeutics.
  • A publication record in peer-reviewed international journals.
  • Citation indicators of 660 citations and an h-index of 17.
  • Methodological breadth spanning synthesis, structure–activity analysis and computational modelling.

Conclusion

Phuong-Thao Tran of Hanoi University of Pharmacy has built a research record centered on the discovery of enzyme inhibitors relevant to Alzheimer’s disease. Her publications, citation metrics and methodological range support her nomination for the Best Researcher Award at the International Academic Achievements & Awards event.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Phuong-Thao Tran, Author ID 55908125500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=55908125500
  2. Hoang, V. H., Tran, P. T., Cui, M., Ngo, V. T. H., Ann, J., Park, J., Lee, J., Choi, K., Cho, H., et al. (2017). Discovery of potent human glutaminyl cyclase inhibitors as anti-Alzheimer’s agents based on rational design. Journal of Medicinal Chemistry, 60(6), 2573–2590.
    https://pubmed.ncbi.nlm.nih.gov/28234463/
  3. Tran, P. T., Hoang, V. H., Thorat, S. A., Kim, S. E., Ann, J., Chang, Y. J., Nam, D. W., et al. (2013). Structure activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. Bioorganic & Medicinal Chemistry.
    https://doi.org/10.1016/j.bmc.2013.08.027
  4. Nguyen, T. H., Tran, P. T., Pham, N. Q. A., Hoang, V. H., Hiep, D. M., & Ngo, S. T. (2022). Identifying possible AChE inhibitors from drug-like molecules via machine learning and experimental studies. ACS Omega, 7(24), 20673.
    https://doi.org/10.1021/acsomega.2c01341
  5. ORCID. (n.d.). Phuong-Thao Tran (ORCID iD 0000-0003-4855-2544). ORCID.
    https://orcid.org/0000-0003-4855-2544

Jing Yu – Pharmacology- Best Researcher Award

Jing Yu - Pharmacology- Best Researcher Award

Shanghai Jiao Tong University - China

Professional Profiles

Early Academic Pursuits

Jing Yu's academic journey began with a solid foundation in pharmaceutical studies. She earned her Bachelor's degree from Shenyang Pharmaceutical University/Jilin University, China, spanning from 1996 to 2000. Building on this, she pursued a Master's degree at Shenyang Pharmaceutical University from 2000 to 2002. These early academic pursuits laid the groundwork for Jing Yu's future endeavors in the field of life sciences.

Professional Endeavors

Professor Assistant at Shanghai Jiao Tong University (2002-2004)

Jing Yu's foray into academia commenced with her role as a Professor Assistant at Shanghai Jiao Tong University from September 2002 to December 2004. During this period, she honed her skills in teaching and research, gaining valuable experience that would shape her academic career.

Ph.D. at University of Basel, Switzerland (2005-2008)

In pursuit of advanced academic and research opportunities, Jing Yu pursued her Ph.D. at the University of Basel in Switzerland from January 2005 to May 2008. This international experience broadened her perspectives and allowed her to engage with a diverse scientific community.

Senior Scientist at University of Geneva, Switzerland (2008-2010)

Jing Yu continued her academic journey as a Senior Scientist at the University of Geneva from June 2008 to August 2010. This role provided her with an opportunity to contribute to cutting-edge research and collaborate with experts in the field.

Assistant and Associate Professor at Shanghai Jiao Tong University (2010-present)

Returning to her alma mater, Jing Yu took on the role of Assistant Professor at Shanghai Jiao Tong University in September 2010. Her dedication and contributions propelled her to the position of Associate Professor in December 2013, solidifying her standing as a prominent figure in the School of Life Sciences and Biotechnology.

Contributions and Research Focus

Jing Yu's research focus revolves around the intricate world of cancer diseases. Specifically, she dedicates her efforts to discovering mediators for therapeutic targets in cancer and studying the mechanisms underlying these diseases. Additionally, her work extends to the critical domain of drug targeting delivery, aiming to enhance the effectiveness of cancer treatments.

Accolades and Recognition

Jing Yu's contributions to the field of cancer research and drug targeting have likely garnered accolades and recognition within the academic community. Awards and honors may have been bestowed upon her, acknowledging the impact of her work on advancing our understanding of cancer therapeutics.

Impact and Influence

Jing Yu's impact is felt through her significant contributions to cancer research. By delving into the complexities of therapeutic targets and drug delivery mechanisms, she has likely influenced the scientific community's approach to cancer treatment. Her work may have implications for developing more targeted and efficient therapies, ultimately benefiting patients.

Legacy and Future Contributions

Jing Yu's legacy is marked by her journey from early academic pursuits to becoming an Associate Professor at Shanghai Jiao Tong University. Her future contributions are anticipated to further shape the landscape of cancer research, leaving a lasting imprint on the understanding and treatment of cancer diseases.

Future Contributions

Looking ahead, Jing Yu envisions expanding her research portfolio to address emerging challenges in cancer therapeutics. Her commitment to advancing drug targeting delivery methods and understanding the intricacies of cancer diseases is expected to lead to innovative solutions with broader applications in the field.

Notable Publications